Overview

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Evaluation of RPH-104 Administered at Different Doses to Patients With Acute Gout Attack

Status:
Unknown status

Trial end date:
2020-01-31

Target enrollment:

Participant gender:

Summary

The primary goal of the study is to evaluate the parameters of efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of RPH-104 in adult patients with acute gout attack.

Phase:

Phase 2

Details

Lead Sponsor:

R-Pharm

Collaborators:

Covance
Data Matrix Solutions
ZAO Unimed Laboratories

Treatments:

Diclofenac